Par Pharmaceuticals' ($PRX) free speech lawsuit against the FDA--coupled with recent Supreme Court action--could prompt a court battle over off-label marketing. "Par's going to blow it wide open," the Coalition for Healthcare Communication's John Kamp tells Medical Marketing & Media. Report